Synthetic Lethality - Its Current Application and Potential in Oncological Treatment.

Area of Science:

• Oncology
• Genetics
• Pharmacology

Background:

• Synthetic lethality involves gene interactions where disrupting one gene is tolerated, but disrupting both leads to cell death.
• The success of poly(ADP-ribose) polymerase (PARP) inhibitors in BRCA1/2-mutated cancers highlights synthetic lethality's therapeutic potential.
• Olaparib, a PARP inhibitor, is a clinically approved treatment for ovarian cancer, demonstrating the translation of synthetic lethality principles into practice.

Purpose of the Study:

• To summarize the current applications of synthetic lethality in oncology.
• To discuss the challenges and future directions in developing new drugs based on synthetic lethality principles.

Main Methods:

• Review of current research and clinical applications of synthetic lethality in cancer treatment.
• Discussion of technological advancements, such as CRISPR/Cas9, in identifying synthetic lethal interactions.
• Analysis of challenges, including incomplete penetrance of synthetic lethality in tumor cell populations.

Main Results:

• PARP inhibitors represent a successful clinical application of synthetic lethality, particularly in BRCA-mutated cancers.
• Ongoing research explores combinations of PARP inhibitors with cell cycle kinase inhibitors to enhance efficacy and overcome resistance.
• Clinical trials are expanding to investigate PARP inhibitor utility in other cancer types, including those with a 'BRCAness' phenotype.

Conclusions:

• Synthetic lethality offers a promising framework for targeted cancer therapy development.
• Further research is needed to address challenges like incomplete penetrance to fully realize the potential of synthetic lethality-based drugs.
• Advancements in screening technologies and combination therapies are crucial for expanding the clinical utility of synthetic lethality.